Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
-0.2%		$257.65
$186.05
▼
$282.15
$16.88B0.35674,395 shs719,506 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$33.60
-2.4%		$30.32
$23.62
▼
$35.43
$20.96B0.841.95 million shs1.00 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
▼
$53.19
$6.12B-0.374.84 million shs6.35 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$487.61
-0.5%		$527.06
$375.61
▼
$609.35
$20.91B0.56492,594 shs326,939 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.43%+8.73%+10.85%+28.83%+35.55%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.56%+0.91%+18.57%+36.82%+27.07%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+611.69%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.36%-7.14%-5.48%-10.84%+25.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
-0.2%		$257.65
$186.05
▼
$282.15
$16.88B0.35674,395 shs719,506 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$33.60
-2.4%		$30.32
$23.62
▼
$35.43
$20.96B0.841.95 million shs1.00 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$51.03
$2.65
▼
$53.19
$6.12B-0.374.84 million shs6.35 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$487.61
-0.5%		$527.06
$375.61
▼
$609.35
$20.91B0.56492,594 shs326,939 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.43%+8.73%+10.85%+28.83%+35.55%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.56%+0.91%+18.57%+36.82%+27.07%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%0.00%0.00%0.00%+611.69%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.36%-7.14%-5.48%-10.84%+25.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$310.0515.58% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5016.85% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.27
Hold$55.144.13% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.85
Moderate Buy$646.0032.06% Upside

Current Analyst Ratings Breakdown

Latest TERN, UTHR, GMAB, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$345.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$306.00 ➝ $304.00
8/27/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/27/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$345.00
8/27/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$345.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M20.54N/AN/A$26.78 per share10.02
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.67$1.59 per share21.26$9.55 per share3.54
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$9.70 per shareN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B6.59$32.79 per share14.92$149.22 per share3.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.8129.67N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2726.6220.872.0319.08%14.89%7.73%11/5/2026 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9517.5016.492.4641.56%20.18%17.98%11/4/2026 (Estimated)

Latest TERN, UTHR, GMAB, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
62.41
62.41
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.78 million614.17 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
40115.52 million113.79 millionNot Optionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable

Recent News About These Companies

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
 |  zacks.comhttps://www.zacks.com/stock/news/2985308/united-therapeutics-uthr-down-8-since-last-earnings-report-can-it-rebound?cid=cs-stocknewsapi-ft-realtime_blog-2985308
United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares
September 4 at 6:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-09-04/
United Therapeutics (NASDAQ:UTHR) Stock Price Down 4.7% on Insider Selling
September 4 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001751
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock
September 3 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-evp-sells-8300-shares-of-stock-2026-09-03/
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock
September 3 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-of-stock-2026-09-03/
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
September 3 at 12:46 PM  |  zacks.comhttps://www.zacks.com/stock/news/2984702/fda-accepts-uthr-s-snda-for-tyvaso-in-idiopathic-pulmonary-fibrosis?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2984702
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Medtronic (MDT)
September 3 at 12:36 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/4423009/analysts-have-conflicting-sentiments-on-these-healthcare-companies-united-therapeutics-uthr-and-medtronic-mdt/
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
September 3 at 12:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fda-accepts-uthrs-snda-tyvaso-154300995.html
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
September 2 at 3:21 PM  |  rutlandherald.comR
United Therapeutics Announces FDA Acceptance Of SNDA For Nebulized Tyvaso In IPF
September 2 at 3:21 PM  |  rttnews.comhttps://www.rttnews.com/3687842/united-therapeutics-announces-fda-acceptance-of-snda-for-nebulized-tyvaso-in-ipf.aspx
United Therapeutics bid to expand nebulized Tyvaso label gets FDA review
September 2 at 3:21 PM  |  msn.comhttps://www.msn.com/en-us/money/general/united-therapeutics-bid-to-expand-nebulized-tyvaso-label-gets-fda-review/ar-AA2bq0WB
United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone
September 2 at 12:31 PM  |  quiverquant.comQ
United Therapeutics (NASDAQ:UTHR) Shares Down 4.7% on Insider Selling
September 2 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-united-therapeutics-nasdaq-uthr-shares-down-47-on-insider-selling-2026-09-02/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $118.21 Million Position in United Therapeutics Corporation $UTHR
September 2 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-has-11821-million-position-in-united-therapeutics-corporation-uthr-2026-09-02/
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock
September 2 at 5:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-09-02/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,855,355.00 in Stock
September 1 at 5:06 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-ceo-sells-485535500-in-stock-2026-09-01/
Two Sigma Securities LLC Purchases 2,216 Shares of United Therapeutics Corporation $UTHR
September 1 at 5:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-purchases-2216-shares-of-united-therapeutics-corporation-uthr-2026-09-01/
Van ECK Associates Corp Has $15.73 Million Stock Holdings in United Therapeutics Corporation $UTHR
September 1 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-van-eck-associates-corp-has-1573-million-stock-holdings-in-united-therapeutics-corporation-uthr-2026-09-01/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,916,345.00 in Stock
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-ceo-sells-491634500-in-stock-2026-08-31/
Public Employees Retirement System of Ohio Invests $13.99 Million in United Therapeutics Corporation $UTHR
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-invests-1399-million-in-united-therapeutics-corporation-uthr-2026-08-31/
Headlands Technologies LLC Invests $4.46 Million in United Therapeutics Corporation $UTHR
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-headlands-technologies-llc-invests-446-million-in-united-therapeutics-corporation-uthr-2026-08-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Computer monitor displaying a candlestick stock price chart breaking above a resistance line, with traders working in a dark office.
3 Stocks Whose Charts May Be Signaling the Next Big Move
By Dan Schmidt | August 9, 2026
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
Red SanDisk external SSD on a gray surface beneath a glowing red SanDisk logo, clean product-style lighting.
Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling
By Sam Quirke | August 6, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$270.56 -0.56 (-0.21%)
As of 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$33.60 -0.81 (-2.35%)
As of 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$487.61 -2.63 (-0.54%)
As of 04:00 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas